ASBMR Responds to FDA Statement on Bisphosphonates; Plans Webinars to Facilitate Discussion
Date: May 09, 2012
The Food and Drug Administration (FDA) announced today that bisphosphonates are effective in reducing common bone fractures in people with osteoporosis, while also recommending that physicians reassess patients after three to five years of therapy to determine whether they should remain on the drug. The full FDA statement appears in an online Perspective of NEJM on May 9, with another Perspective by Black et al. ASBMR has issued a release in response to the FDA article that is available on its website.
To help researchers and physicians understand the implications of the FDA recommendations and factors to consider for patients taking bisphosphonates, ASBMR will host two webinars in the coming weeks. The first webinar on the Efficacy and Safety of Long-Term Use of Bisphosphonates for the Treatment and Prevention of Osteoporosis will be held on May 17th and facilitate further discussion of the scientific evidence regarding bisphosphonates. The webinar speakers will include Dr. Theresa Kehoe with the FDA Center for Drug Evaluation as well as several ASBMR experts.
The second webinar on Case Studies on the Management of Patients on Bisphosphonates for the Treatment and Prevention of Osteoporosis will be held in late May and facilitate further discussion of the management of patients on bisphosphonates. To register for either webinar, visit http://www.asbmr.org/Education/Webinars.aspx.